Get the Stockscreener App
1.34
6.35%
0.08
Pre-market:
1.32
-0.02
-1.49%
Marker Therapeutics Inc stock is traded at $1.34, with a volume of 189.12K.
It is up +6.35% in the last 24 hours and down -13.55% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
See More
Previous Close:
$1.26
Open:
$1.27
24h Volume:
189.12K
Relative Volume:
0.62
Market Cap:
$22.34M
Revenue:
$3.55M
Net Income/Loss:
$-12.16M
P/E Ratio:
-1.4733
EPS:
-0.9095
Net Cash Flow:
$-12.01M
1W Performance:
+0.00%
1M Performance:
-13.55%
6M Performance:
+52.00%
1Y Performance:
+12.61%
1-Day Range:
$1.27
$1.40
1-Week Range:
$1.17
$1.40
52-Week Range:
$0.8099
$4.07
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.34 | 22.34M | 3.55M | -12.16M | -12.01M | -0.9095 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Insider Sell: Can Marker Therapeutics Inc deliver consistent dividends2026 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exit Recap: Should I hold or sell Marker Therapeutics Inc now2026 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
MRKR SEC FilingsMarker Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday - Defense World
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
Q2 Earnings Estimate for MRKR Issued By Brookline Cap M - Defense World
Form DEF 14A Marker Therapeutics For: 20 March - Investing.com
Marker Therapeutics (NASDAQ: MRKR) proxy eyes 130M shares, lower vote hurdle - Stock Titan
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones - TipRanks
Marker Therapeutics, Inc. 2025 10-K: Clinical-Stage Immuno-Oncology Pipeline, Regulatory Strategy, and Competitive Landscape Overview - Minichart
MARKER THERAPEUTICS, INC. (MRKR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Marker Therapeutics (MRKR) outlines MAR-T cancer pipeline, MT-601 trials and grant funding - Stock Titan
Marker Therapeutics 10-K: Revenue $3.55M; Net loss $12.18M - TradingView
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income - TradingView
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology - Quiver Quantitative
MRKR: Net loss widened to $12.2M in 2025 as clinical programs advanced, with cash runway through Q4 2026 - TradingView
Marker Therapeutics (NASDAQ: MRKR) reports 2025 loss and cash runway into late 2026 - Stock Titan
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewswire
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pullback Watch: Can Marker Therapeutics Inc outperform in the next rally2026 Support & Resistance & High Accuracy Investment Signals - baoquankhu1.vn
Tangible book value per share of Marker Therapeutics, Inc. – MUN:GX1 - TradingView
Aug Weekly: What is the long term forecast for Marker Therapeutics Inc stockPrice Action & AI Driven Stock Reports - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Marker Therapeutics (MRKR) - The Globe and Mail
Marker Therapeutics (NASDAQ: MRKR) seeks approval to raise authorized shares to 130M - Stock Titan
Will Marker Therapeutics Inc. stock outperform value stocks2025 Big Picture & Weekly Momentum Stock Picks - Naître et grandir
Market Pulse: Does Marker Therapeutics Inc have pricing powerJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
What is the long term forecast for Marker Therapeutics Inc stockPortfolio Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
MRKR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
MRKR: First-in-class MAR-T cell therapy shows high efficacy and safety in refractory lymphoma - TradingView
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
How buybacks impact Marker Therapeutics Inc. stock value2025 Top Decliners & AI Based Buy/Sell Signal Reports - mfd.ru
Is Marker Therapeutics Inc. stock a safe buy before earningsMarket Weekly Review & Fast Moving Stock Trade Plans - mfd.ru
Marker Therapeutics sets date for 2026 annual shareholder meeting and proposal deadline - Investing.com Nigeria
Marker Therapeutics Sets Date for 2026 Annual Meeting - TipRanks
Portfolio Update: Why is Mattel Inc stock going upJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Hematopoietic Stem Cell Transplantation (HSCT) Market Booming with Rapid Growth Through 2033 | CellGenix GmbH - EIN News
Can BioSig Technologies Inc benefit from deglobalizationPortfolio Performance Report & Safe Entry Trade Reports - baoquankhu1.vn
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology - manilatimes.net
Good Morning America puts Baylor T-cell cancer trial in national spotlight - Stock Titan
Good Morning America Features Baylor College of Medicine - GlobeNewswire
Institution Moves: Should I trade or invest in One Liberty Properties IncJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
MRKR stock up nearly 114% in 3 months: Here's what you need to know - MSN
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Risk Analysis: Can Marker Therapeutics Inc outperform in the next rallyJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Published on: 2026-01-20 15:10:37 - baoquankhu1.vn
Whale Trades: Does REBN have consistent dividend growthTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Marker Therapeutics (NASDAQ:MRKR) Cut to “Hold” at Zacks Research - Defense World
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):